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Background: Cyclin-dependent kinase 4 (CDK4) together with its regulatory subunit cyclin D1, governs cell cycle
progression through G1 phase. Cyclin-dependent kinase inhibitors, including p16
INK4A in turn regulate CDK4. In
particular, deregulation of the p16/CDK4/cyclin D1 complex has been established in a variety of human tumors
including gliomas, sarcomas, melanoma, breast and colorectal cancer. However, changes in CDK4 have rarely been
observed.
Method: In this study we used a combination of PCR-SSCP and direct sequencing for mutational screening of
CDK4. DNA was isolated from peripheral blood leukocyte of patients with squamous cell carcinoma of head and
neck, for screening germline mutations in coding regions of CDK4.
Results: Variations observed in exon 2 and 5 were three missense mutations, g5051G > C (Ser52Thr), g5095G > C
(Glu67Gln), g5906C > A, g5907C > G (Pro194Ser) and novel frame shift mutations g7321_23delTGA,
g7121_7122insG, g7143delG in exon 7 and 30UTR respectively.
Conclusion: In conclusion, two novel mutations were found in N terminal domain which indicates that CDK4
mutation may play a major role in the development and progression of squamous cell carcinoma of head and
neck.
Keywords: CDK4, germ line mutations, SSCP, squamous cell carcinoma of head and neck, Pakistani populationBackground
Cyclin-dependent kinases (Cdks) are serine/threonine
kinases that regulate progression through cell cycle.
CDK4 and CDK6 act early in the cell cycle and are
involved in the transition from G1 to S phase [1]. Loss of
G1 control in cell cycle appears to be an important step
contributing to tumorigenesis [2]. D-type cyclin and
their kinase partners, CDK4 and CDK6, coordinately
phosphorylate the Rb protein, thereby releasing the tran-
scription factor at G1 and then progressions into the S
phase occurs [3]. In addition to role in cell cycle, there is
increasing evidence that Cdks, as well as cyclin and
cyclin-dependent kinase inhibitors are important for
other cellular functions, including cytoskeleton re-
arrangement and cell migration [4]. CDK4 is a potential
oncogene, located on chromosome 12q13; mechanisms
of activation could include gene amplification, over-* Correspondence: mkayani@comsats.edu.pk
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reproduction in any medium, provided the orexpression, decreased degradation, and activating point
mutations. The CDK4 is amplified and over expressed in
a number of human tumors including the gliomas, sar-
comas, breast tumors and colorectal carcinomas [5]. In
humans, rare point mutations in the CDK4 have been
described worldwide [6]. All CDK4 reported mutations
are located in exon 2, which codes for the p16INK4A
binding site [7]. Derailments of Rb pathway caused ei-
ther by lack of Rb gene (pRb1-CycinD1-Cdk4/6-p16INK4)
expression and over expression of Cdks are implicated in
the deregulation of cell cycle machinery, resulting in un-
controlled growth, tumor heterogeneity, invasion and
metastasis [8].
Aim of study was to investigate a possible disruption of
Rb suppression pathway by germline mutational analysis in
the p16-binding and cyclin D1 binding domain of CDK4 in
squamous cell carcinoma of head and neck in Pakistani
population. Furthermore, to determine association of novel
mutations in CDK4 and risk of squamous cell carcinoma of
head and neck, we performed polymerase chain reaction,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 List of primers with annealing temperature and product size (bp)
Exon No Primer sequence (Forward) F Primer sequence (Reverse) R Product size (bp) Annealing temperature °C
1 TCACGTGCCCAGAACGTC CTCATTCCTGGGAAGGGACT 266 56
2 AAGCGACTTTTGGTGATAGGA TTACTCCCCACGCCCAAC 308 54
3 GAGAGGCCATGTTGGGTTAA TCCACCTCTCAATGCCTACC 222 58
4 TCTGGGATTTCAGGTATGGTG ATTGCTACGGGCAATCACTC 295 58
5 GTGTTTCATGGTAACCCATGG TTTATGAACAAGCGATTTGGG 219 58
6 TCTTTGAAAATGACTGCTACCTT CCTGGGTTCAGCAGAAAGAG 156 58
7 AGGACCCTCCTGACCAGAGT CTTTCCCTGTGCCCACAG 205 60
8 TCATGGTTTTCTGACCTTTGC GCCCTCTCAGTGTCCAGAAG 190 58
Table 2 Characteristics of head and neck cancer patients





Mean (±S.D) 38 (±16.35)*
<40 271 (71%)
>40 109 (29%)








Non smokers 238 (62.5%)
Smokers 142 (37.5%)
* Mean age, 38 years (±S.D).
* Cancer type include squamous cell carcinoma of oral cavity, pharynx and
larynx.
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sequence analysis.
Materials and methods
Sample collection and clinical data
The present study was conducted with a prior approval
from ethical committees of both department and hospi-
tals. Blood samples from total of 380 patients with histo-
logical confirmed squamous cell carcinoma of head and
neck, including oral cavity, pharynx and larynx were col-
lected from National Oncology and Radiotherapy Insti-
tute (NORI), Pakistan Institute of Medical Sciences
(PIMS) and Military Hospital (MH). A total of 350 age,
gender, and ethnicity matched cancer free healthy indivi-
duals were selected as controls. Patients and controls
suffering from any other familial disease (diabetes, blood
pressure and cardiovascular impairment) were excluded
from this study. After obtaining informed consent, all
individuals were personally interviewed using a specific-
ally designed questionnaire.
DNA extraction
Blood samples from patients and normal individuals
(control), belonging to the same age and gender were
collected in tubes containing EDTA and stored at 4°C.
DNA was extracted from white blood cells, using stand-
ard phenol-chloroform extraction method [9,10] and
stored at -20°C for further processing. Electrophoresis
was performed on isolated DNA in 1% ethidium-
bromide stained agarose gel and photographed (BioDoc
Analyze Biometra).
Polymerase chain reaction (PCR)
Human CDK4 sequence was taken from Ensemble. Pri-
mers were designed by using PRIMER 3 INPUT SOFT-
WARE version 0.4.0 (Table 1). Coding regions and their
exon/intron boundaries of approximately 60 bp se-
quence of were investigated to identify any splice site
variation as well. Each PCR reaction was performed in a
20 μl reaction mixture containing approximately 20 ng
of genomic DNA templates, 2 μl (10 mM) of eachprimer, 0.24 μl (25 mM) of dNTP, 2 μl (10x) PCR buffer
and 0.2 μl (5u/μl) of Taq polymerase. PCR profile con-
sisted of an initial melting step of 94°C for 5 min,
35 cycles of 94°C for 45 s, annealing temperature for
1 min and 72°C for 1 min and a final extension step of
72°C for 10 min and hold at 4°C.
Mutational screening and sequence analysis
Amplification products were resolved on a 2% ethidium
bromide containing agarose gel along with 100 bp DNA
ladder. PCR products were analyzed by single stranded
conformational polymorphism (SSCP) [11] and results
were analyzed with the gel documentation system (Bio-
DocAnalyze, Biometra). Samples with an altered mobility
patterns were reamplified and than analyzed by direct
sequencing to confirm and characterize the nature of
Figure 1 (See legend on next page.)
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Figure 1 a: Mutations in CDK4 detected by PCR-SSCP analysis in head and neck cancer samples, digital image of an ethidium bromide
stained 8% non denaturing polyacrylamide gel showing band pattern. Arrow head indicates change in band shift. C represents HNC cases
and N represents normal samples. b: Sequencing electropherogram of mutations in CDK4: (A) Missense g5051G>C mutation, (CM994495) in
exon 2 showing G to C substitution resulting in change of DNA sequences from AGC to ACC encoding amino acid threonine instead of serine,
(B) Missense mutation, g5095G>C (Novel) in exon 2 showing G to C substitution resulting in change of DNA sequence from GAG to CAG
encoding the amino acid glutamine instead of glutamate, (C) Missense mutations, g5906C>A, g5907C>G in exon 5 changing the DNA
sequence from CCT to AGT encoding the amino acid serine instead of proline, (D) Frame shift mutation in 30UTR as a result of insertion of
nucleotide G, (g7121_7122insG), (E) Frame shift mutation in 30UTR as a result of deletion of nucleotide G (g7143delG), (F) Missense mutation
g7320A>C and frameshift mutation g7321_23delTGA in exon 7.
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(USA). Control (normal) samples were also sequenced
along with cases to avoid false negative results and check
the quality of sequencing.
Statistics and bioinformatic analysis
χ2-test with Fisher exact test was used to evaluate the
differences in selected demographic variables by using
the SPSS 17.0 software, odd ratios (OR) and 95% confi-
dence interval (CI) were calculated. Bioinformatic ana-
lysis for homology modeling was performed using




The features of our population are listed in Table 2.
These 380 patients have mean age of 38.1 years at diag-
nosis. The mean age of controls (35 ±12.23 years) was
slightly different from cases (38 ± 16.35), but the differ-
ence was not significant (p < 0.86). Statistically significant
increase in incidence of head and neck cancer was
observed in age group of <40 years as compare to age
group > 40 (p < 0.05) (Table 2).
PCR-SSCP and direct sequence analysis
To investigate whether alterations of the CDK4 were
present in the squamous cell carcinoma of head and
neck, we screened the coding regions (exons 1–8) as
well as intron/exon boundaries of CDK4 using PCR-Table 3 Frequency of CDK4 mutations in squamous cell carcin
Region in gene Mutations Mutation
Exon 2 g5051G>C* Missense
Exon 2 g5095G>C Missens
Intron 3 g5427delA -
Exon 5 g5906C>A, g5907C>G Missens
Exon 7 g7320 A>C, g7321_23delTGA Frame sh
30 UTR g7121_7122insG Frame sh
30 UTR g7143delG Frame sh
* Reported mutation with CM994495 coding unknown *http://www.ensembl.org/Ho
r=12:58142034–58149796;v=CM994495;vdb=variation;vf=44643002.SSCP. Figure 1 (a & b) summarizes the results of PCR-
SSCP and direct sequence analysis. In this study differ-
ent types of mutations were identified in exon 2, 5, 7
and 30UTR. No alteration in exon 1, 3, 4, 6 and 8 of
CDK4 was detected in any of cases.
Study revealed a reported missense mutation g5051G>
C (CM994495) in exon 2 show G to C substitution
resulting in change of nucleotide sequences from AGC
to ACC, encoding amino acid threonine instead of
serine. A novel missense mutation g5095G>C resulting
in change of nucleotide sequence from GAG to CAG,
encoding the amino acid glutamine instead of glutamate.
Study includes other novel missense mutations,
g5906C >A and g5907C >G, in exon 5 changing the nu-
cleotide sequence from CCT to AGT, encoding the
amino acid serine instead of proline. A novel missense
g7320A >C mutation and a frame shift mutation
g7321_23delTGA was also detected in exon 7. Two
novel frame shift mutations were observed in 30UTR as
a result of insertion of nucleotide G (g7121_7122insG)
and deletion of nucleotide G (g7143delG) (Table 3). No
such mutation was present in control samples. Oral cav-
ity cases have more mutation compare to pharyngeal
and laryngeal carcinoma but difference was statistically
non significant [p= 0.13, OR 84.0, 95% CI (65.69 to
233.69)]. Significant difference was observed in smokers
and non-smokers patients having missense and frame
shift mutations [p= 0.03, OR 1.84, 95% CI (1.33 -2.54)]
(Table 4). To verify whether the Arg24Cys mutation in
the CDK4 was present in squamous cell carcinoma, weoma of oral cavity, pharynx & larynx














Area of cancer Smoking status
Oral cavity (N= 224) Pharynx (N= 97) Larynx (N= 59) Non smoker (N= 238) Smokers (N= 142)
Exon 2 g5051G>C 24 19 06 19 30
Exon 2 g5095G>C 22 15 08 22 23
Intron 3 g5427delA 18 11 02 17 14
Exon 5 g5906C>A, g5907C>G 15 08 04 15 12
Exon 7 g7320 A>C, g7321_23delTGA 20 03 01 13 11
30 UTR g7121_7122insG 27 12 07 22 24
30 UTR g7143delG 23 05 02 12 18
Total 149 73 30 120 132
p = 0.13 p = 0.03
OR 84.0, 95% CI (65.69 to 233.69) OR 1.84, 95% CI (1.33 -2.54)
N = number of cases.
Odd ratio (OR).
95% confidence interval (CI).
Figure 2 Multiple sequence alignment of CDK4 protein generated with ClustalW 2.1. The locations of two of the point mutations reported
here are marked with arrows, and one previously reported mutation , Sequences from five different species were included in the alignment:
Human [P11802], mouse [P30285], sheep [B2MVY4] cow bovine [Q32KY4] and frog[Q91727].
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Figure 3 CDK4 protein structure indicating the N-terminal and
C-terminal domain. The mutations Ser52Thr, Glu67Gln and
Pro194Ser are represented in the structure, using The UCSF Chimera
1.5.3 program.
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mutation mapped by PCR-SSCP and subsequent se-
quence analysis. Both SSCP and sequence analysis
showed that Arg24Cys mutation was not present in any
of our cases.
Discussion
The Rb pathway has been shown to be frequently altered
in human cancers [12-15]. CDK4 is a member of the
Ser-Thr protein kinase family and its catalytic domain
extends from amino acid 6 to 295. CDK4 consists of
eight exons, of which the start codon is located in the
beginning of exon 2 and the stop codon in the beginning
of exon 8 [16]. Multiple sequence alignment of CDK4
protein was generated with ClustalX, including
sequences from five different species was constructed.
As shown in Figure 2, the human and sheep cdk4-
protein sequences have a higher level of identity than
the average human-mouse sequence identity (97% versus
94%).
In present study germline mutational analysis of CDK4
revealed two missense mutations, Ser52Thr and
Glu67Gln on exon 2. However, to date, only two muta-
tions in this region, an arginine-to-cysteine missense
mutation [17] and an arginine-to-histidine mutation in
the germ line of one French melanoma-prone family [6]
in codon 24 and 22 have been reported respectively.
This mutation at codon 24, as a result of change of a
single nucleotide (CGT to TGT) change arginine to cyst-
eine (R24C) is an activating mutation, as it results in
growth advantages, because it prevents p16 binding [18].
A prior study found that mutations that decreased cyclin
binding of CDK4 by greater than 80% also decreased
kinase activity [19]. Generally, the level of cyclin binding
of the various CDK4 mutants correlates well with kinase
activity, and the sequences involved in p16INK4a binding
are a subset of those involved in cyclin D1 binding [20].
Figure 3 shows In silico structural model analysis of
CDK4 protein using the UCSF Chimera 1.5.3 program
revealed that Ser52Thr and Glu67Gln mutations are
located in N terminal domain contain αC helix (aa 1–
96). That compromise of PISTVRE sequence is import-
ant for protein function and binding of cyclin D [21].
In our study three novel frame shift mutations were
found on exon 7 and 30UTR. Frame shift mutation
observed in coding region g7321_23delTGA is changing
the whole downstream sequence of gene. As a result
translation of wrong reading frame continues and the re-
sultant premature RNA stability is compromised so ei-
ther mRNA will not stable or protein degradation
happen [22]. Although genetic alterations in 30 UTR
sequences can modify the binding properties of trans-
acting factors and lead to deregulation in protein pro-
duction [18]. But most studies have sought to identifymutations in the coding region and very few naturally
occurring mutations in non coding areas have been
described to date. Pakistan harbors vast genetic, ethnic,
cultural, social and life style diversity. In present study a
group is characterized by onset of cancer frequently be-
fore the age of 40 year. Clinically, one key feature of gen-
etic bases of cancer is early age at onset. Similar trends
have been reported for familial melanoma, breast and
colon cancers. Early disease onset has been associated
with an increased prevalence of germline mutations [23].
Amplification and over expression of CDK4 has been
detected in sarcoma and glioma, but in carcinoma the
picture seems to be unclear. Only sporadic data are
available in carcinoma where very low percentage of
amplification was reported [24]. CDK4 is altered in mel-
anoma patients by a miscoding mutation (Arg24Cys)
that blocks binding of INK4 inhibitors. However, the
causal role of these alterations in tumor development is
difficult to assess [25]. Present study revealed that there
was no germline mutation in codon 24 and 22 of CDK4
and these results support the findings of previous studies
[20,26,27]. The potentially dominant Arg24Cys mutation
of CDK4 was not detected in Indian patients with squa-
mous cell carcinoma of head and neck [8]. CDK4 muta-
tions reported in the literature are rare and little is
known about the functional implications of these
changes [28]. Study using in vitro site-directed mutagen-
esis analyzed that disruption of either codon 22 or
codon 24 effectively abrogates interaction with cyclin Dl
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germ-line Arg24Cys mutation, revealed no documented
changes in p16/CDKN2A binding site of CDK4 [29].
Conclusion
In conclusion Arg24Cys mutation plays a key role in dif-
ferent cancers but in the current study we were unable
to detect this mutation. This suggests that CDK4 novel
germline mutations observed in study may play a differ-
ent and important role in squamous cell carcinoma of
head and neck cancer in Pakistani population. Potential
of these novel mutations in head and neck carcinogen-
esis need to be explored in order to ascertain there po-
tential importance.
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